LivaNova PLC (LIVN)

LivaNova PLC is trading at $80.16, up 0.44% on the session. The 50 day average sits at $80.51 and the 200 day at $69.13, which puts the stock in a uptrend. RSI is at 51.7, which reads as neutral, and MACD is bullish crossover. Volume is below average.

The nearest support is around $78.07 with resistance near $80.96, so that band frames the current range. Average daily movement is roughly $2.36, or about 2.9% of the share price, which is what any stop placement has to allow for. The overall health score of 63 out of 100 combines a trend score of 61, momentum of 65 and a risk score of 64.

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.